The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
#EULAR2024: Transition and patient outcomes
To update you on the exciting content presented at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress, we have collated our social media coverage. Catch up with our live social media relating to transition, patient outcomes, and other key tweets, here.
Transition
CONGRESS #EULAR2024 | @DrMariola presented data on biomarkers of transition from PsO to PsA. Patients were selected if there was no exposure to biologic before rheumatological assessment. In the skin there is an increase in mReg DCs in lesional skin of patients at risk of PsA.… pic.twitter.com/N1l4aNHAzT
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 14, 2024
CONGRESS #EULAR2024 | POSTER: Sofia Ferreira Azevedo presented a poster on preventing PsA in patients with psoriasis. bDMARDs were found to reduce the risk for progression to PsA compared to other treatments. #psoriaticarthritis pic.twitter.com/6r31dgNBtg
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 14, 2024
CONGRESS #EULAR2024 | Dr. Beatriz Joven-Ibáñez presented data from a TRINETX global population study of transition risk from PsO to PsA with biologics. Assessed 1,175,000 patients with PsO. Incidence of PsA was higher in patients treated with TNFis vs ILis. #psoriasis… pic.twitter.com/Ct1wInDcDX
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 12, 2024
Patient outcomes
CONGRESS #EULAR2024 | POSTER: Dr. Philip J. Mease presented a poster on data from the phase IV MOSAIC study. At Weeks 24 and 48, patients treated with apremilast showed significant improvement in PROs, MRI (of the hand), and clinical outcomes. MRI can be a valuable tool for… pic.twitter.com/KnRjmEjBY5
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 14, 2024
CONGRESS #EULAR2024 | POSTER: Pasal H.P. de Jong presented a poster on the association between depression and anxiety and achieving remission in PsA. Having depression or anxiety was associated with more tender joints and increased pain, and these patients were less likely to… pic.twitter.com/yN2ZKnS7hV
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 14, 2024
Other
CONGRESS #EULAR2024 | Dr. Alan Kivitz presented the safety and efficacy of zasocitinib (TAK-279) over 12 weeks. TEAEs were highest in the 30mg group vs 15mg and 5mg. There were no TEAEs leading to death. Efficacy of zasocitinib was superior compared to placebo. #psoriasis… pic.twitter.com/Hmb5LoYPbQ
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 13, 2024
CONGRESS #EULAR2024 | Prof. Adrian Ciurea presented data on resolution of joint swelling in different locations with TNFis in PsA. N = 1729. After TNFi, the elbow and shoulder saw higher resolution compared to the wrist. Differences did not depend on the size of the joint.… pic.twitter.com/2xXYC6xN4H
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 12, 2024
CONGRESS #EULAR2024 | Dr Erik Lubberts discussed the BRIGHT concept that intestinal microbiota shapes immune response in PsA. T cells are linked to gut inflammation and disease activity. Findings suggest there is potentially higher inflammation axial and polyarthritis PsA… pic.twitter.com/S9e8Wdbyhr
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 14, 2024
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content